Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Ann Surg Oncol. 2011 Nov;18(12):3353-61. doi: 10.1245/s10434-011-1747-7. Epub 2011 May 3.
Approximately half of patients who undergo curative resection for esophageal cancers develop recurrence postoperatively. The factors affecting survival after such recurrence remain largely unknown.
To investigate factors affecting survival after recurrence in patients who had undergone curative resection for esophageal cancer, we retrospectively reviewed data for 461 patients who underwent curative esophagectomy with or without preoperative therapy for esophageal squamous cell carcinoma from January 1996 to December 2007. The correlations between several clinicopathological factors and survival after recurrence were examined.
Recurrence occurred in 196 of 461 patients (42.5%), with a median survival time after recurrence of 8.2 months. Multivariate analysis identified advanced tumor stage, preoperative chemoradiotherapy (CRT), number of recurrent tumors, and the presence of recurrence at the local site and liver as associated with shortened survival after recurrence. The analysis also indicated that treatment of the recurrence prolonged survival regardless of the treatment type. Although the pattern of recurrence did not significantly differ according to type of preoperative therapy, patients who underwent preoperative CRT were less often treated with radiotherapy for recurrence. Patients with multiple recurrent tumors less often received radiotherapy or surgery than those with a solitary recurrence. Chemotherapy for recurrence was not associated with either preoperative therapy or the number of recurrences.
Our retrospective study showed that multiple recurrent tumors and preoperative CRT limit the available treatment for recurrence and thereby are associated with poor prognosis. Vigorous treatment for recurrence can extend survival after recurrence in patients who undergo esophagectomy.
大约一半接受食管癌根治性切除术的患者术后会复发。影响此类复发后生存的因素在很大程度上尚不清楚。
为了研究接受根治性食管癌切除术的患者复发后影响生存的因素,我们回顾性分析了 1996 年 1 月至 2007 年 12 月期间接受根治性食管切除术的 461 例食管鳞癌患者的临床病理资料。研究了几种临床病理因素与复发后生存的相关性。
461 例患者中有 196 例(42.5%)发生复发,复发后中位生存时间为 8.2 个月。多因素分析显示,肿瘤分期较晚、术前放化疗(CRT)、复发肿瘤数目、局部和肝脏复发与复发后生存时间缩短相关。分析还表明,无论治疗类型如何,治疗复发均可延长生存。尽管根据术前治疗类型,复发模式无显著差异,但接受术前 CRT 的患者较少接受局部复发的放疗。与单发复发相比,多发复发的患者较少接受放疗或手术治疗。复发时化疗与术前治疗或复发次数无关。
我们的回顾性研究表明,多发复发和术前 CRT 限制了对复发的治疗选择,从而与预后不良相关。对接受食管癌切除术的患者进行积极的复发治疗可以延长复发后的生存时间。